Cadrenal initiates formal strategic review for asset sales or M&A

Cadrenal's Board has authorized a formal strategic process to evaluate licensing, asset sales, partnerships, or business combinations to maximize shareholder value. The review is preliminary with no deadline, but signals the company is actively exploring value-accretive transactions that could include M&A.

Cadrenal's board is looking for ways to boost the company's value by potentially selling assets, finding partners, or merging with another company—a signal often tied to reorganization or acquisition activity.